Summary

Syphilis Immunoassay Diagnostics Market – Scope of Report
TMR’s report on the global syphilis immunoassay diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global syphilis immunoassay diagnostics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global syphilis immunoassay diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the syphilis immunoassay diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global syphilis immunoassay diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global syphilis immunoassay diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global syphilis immunoassay diagnostics market.

The report delves into the competitive landscape of the global syphilis immunoassay diagnostics market. Key players operating in the global syphilis immunoassay diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global syphilis immunoassay diagnostics market profiled in this report.

Key Questions Answered in Global syphilis immunoassay diagnostics Market Report
• What is the sales/revenue generated by syphilis immunoassay diagnostics across all regions during the forecast period?
• What are the opportunities in the global syphilis immunoassay diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Syphilis Immunoassay Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global syphilis immunoassay diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global syphilis immunoassay diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global syphilis immunoassay diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Syphilis Immunoassay Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Key Industry Events
5.2. Distributors Landscape
5.3. PORTER’s Five Forces Analysis
5.4. End-user Preference
5.5. Epidemiology of Syphilis by Region/Countries
5.6. Government Initiatives by Region/Countries
5.7. Healthcare Expenditure by Region/Country (Health spending Total, US dollars/capita, 2022)
5.8. PESTEL Analysis
5.9. Impact of near patient testing and POC on syphilis market dynamics
5.10. Brand and Pricing Analysis
5.11. Regulatory Scenario by Region/ Country
5.12. Supply Chain Analysis
5.13. Technological Advancements
6. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2020-2034
6.3.1. Analyzer
6.3.2. Kits & Reagents
6.4. Market Attractiveness By Product
7. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Technology
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Technology, 2020-2034
7.3.1. Chemiluminescence Assay (CLIA)
7.3.2. Enzyme Linked Immunosorbent Assay (ELISA
7.3.3. Immunochromatographic Assay /Lateral Flow Assay
7.3.4. Treponema pallidum latex agglutination (TPLA)
7.3.5. Non-treponemal Flocculation Assay
7.4. Market Attractiveness By Technology
8. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Test Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Test Type, 2020-2034
8.3.1. Treponemal Tests
8.3.2. Non-Treponemal Tests
8.4. Market Attractiveness By Test Type
9. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Location of Testing
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Location of Testing, 2020-2034
9.3.1. Point-of-care testing (POCT)
9.3.2. Patient Self-Tests (PST)
9.3.3. Clinical Settings
9.4. Market Attractiveness By Location of Testing
10. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By End-user, 2020-2034
10.3.1. Hospitals and Clinics
10.3.2. Diagnostics Laboratories
10.3.3. Home Care
10.3.4. Public Health Laboratory
10.3.5. Others
10.4. Market Attractiveness By End-user
11. Global Syphilis Immunoassay Diagnostics Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Country/Region
12. North America Syphilis Immunoassay Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product, 2020-2034
12.2.1. Analyzer
12.2.2. Kits & Reagents
12.3. Market Value Forecast By Technology, 2020-2034
12.3.1. Chemiluminescence Assay (CLIA)
12.3.2. Enzyme Linked Immunosorbent Assay (ELISA
12.3.3. Immunochromatographic Assay /Lateral Flow Assay
12.3.4. Treponema pallidum latex agglutination (TPLA)
12.3.5. Non-treponemal Flocculation Assay
12.4. Market Value Forecast By Test Type, 2020-2034
12.4.1. Treponemal Tests
12.4.2. Non-Treponemal Tests
12.5. Market Value Forecast By Location of Testing, 2020-2034
12.5.1. Point-of-care testing (POCT)
12.5.2. Patient Self-Tests (PST)
12.5.3. Clinical Settings
12.6. Market Value Forecast By End-user, 2020-2034
12.6.1. Hospitals and Clinics
12.6.2. Diagnostics Laboratories
12.6.3. Home Care
12.6.4. Public Health Laboratory
12.6.5. Others
12.7. Market Value Forecast By Country, 2020-2034
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Product
12.8.2. By Technology
12.8.3. By Test Type
12.8.4. By Location of Testing
12.8.5. By End-user
12.8.6. By Country
13. Europe Syphilis Immunoassay Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product, 2020-2034
13.2.1. Analyzer
13.2.2. Kits & Reagents
13.3. Market Value Forecast By Technology, 2020-2034
13.3.1. Chemiluminescence Assay (CLIA)
13.3.2. Enzyme Linked Immunosorbent Assay (ELISA
13.3.3. Immunochromatographic Assay /Lateral Flow Assay
13.3.4. Treponema pallidum latex agglutination (TPLA)
13.3.5. Non-treponemal Flocculation Assay
13.4. Market Value Forecast By Test Type, 2020-2034
13.4.1. Treponemal Tests
13.4.2. Non-Treponemal Tests
13.5. Market Value Forecast By Location of Testing, 2020-2034
13.5.1. Point-of-care testing (POCT)
13.5.2. Patient Self-Tests (PST)
13.5.3. Clinical Settings
13.6. Market Value Forecast By End-user, 2020-2034
13.6.1. Hospitals and Clinics
13.6.2. Diagnostics Laboratories
13.6.3. Home Care
13.6.4. Public Health Laboratory
13.6.5. Others
13.7. Market Value Forecast By Country, 2020-2034
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Product
13.8.2. By Technology
13.8.3. By Test Type
13.8.4. By Location of Testing
13.8.5. By End-user
13.8.6. By Country
14. Asia Pacific Syphilis Immunoassay Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product, 2020-2034
14.2.1. Analyzer
14.2.2. Kits & Reagents
14.3. Market Value Forecast By Technology, 2020-2034
14.3.1. Chemiluminescence Assay (CLIA)
14.3.2. Enzyme Linked Immunosorbent Assay (ELISA
14.3.3. Immunochromatographic Assay /Lateral Flow Assay
14.3.4. Treponema pallidum latex agglutination (TPLA)
14.3.5. Non-treponemal Flocculation Assay
14.4. Market Value Forecast By Test Type, 2020-2034
14.4.1. Treponemal Tests
14.4.2. Non-Treponemal Tests
14.5. Market Value Forecast By Location of Testing, 2020-2034
14.5.1. Point-of-care testing (POCT)
14.5.2. Patient Self-Tests (PST)
14.5.3. Clinical Settings
14.6. Market Value Forecast By End-user, 2020-2034
14.6.1. Hospitals and Clinics
14.6.2. Diagnostics Laboratories
14.6.3. Home Care
14.6.4. Public Health Laboratory
14.6.5. Others
14.7. Market Value Forecast By Country, 2020-2034
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Product
14.8.2. By Technology
14.8.3. By Test Type
14.8.4. By Location of Testing
14.8.5. By End-user
14.8.6. By Country
15. Latin America Syphilis Immunoassay Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product, 2020-2034
15.2.1. Analyzer
15.2.2. Kits & Reagents
15.3. Market Value Forecast By Technology, 2020-2034
15.3.1. Chemiluminescence Assay (CLIA)
15.3.2. Enzyme Linked Immunosorbent Assay (ELISA
15.3.3. Immunochromatographic Assay /Lateral Flow Assay
15.3.4. Treponema pallidum latex agglutination (TPLA)
15.3.5. Non-treponemal Flocculation Assay
15.4. Market Value Forecast By Test Type, 2020-2034
15.4.1. Treponemal Tests
15.4.2. Non-Treponemal Tests
15.5. Market Value Forecast By Location of Testing, 2020-2034
15.5.1. Point-of-care testing (POCT)
15.5.2. Patient Self-Tests (PST)
15.5.3. Clinical Settings
15.6. Market Value Forecast By End-user, 2020-2034
15.6.1. Hospitals and Clinics
15.6.2. Diagnostics Laboratories
15.6.3. Home Care
15.6.4. Public Health Laboratory
15.6.5. Others
15.7. Market Value Forecast By Country, 2020-2034
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Product
15.8.2. By Technology
15.8.3. By Test Type
15.8.4. By Location of Testing
15.8.5. By End-user
15.8.6. By Country
16. Middle East & Africa Syphilis Immunoassay Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Product, 2020-2034
16.2.1. Analyzer
16.2.2. Kits & Reagents
16.3. Market Value Forecast By Technology, 2020-2034
16.3.1. Chemiluminescence Assay (CLIA)
16.3.2. Enzyme Linked Immunosorbent Assay (ELISA
16.3.3. Immunochromatographic Assay /Lateral Flow Assay
16.3.4. Treponema pallidum latex agglutination (TPLA)
16.3.5. Non-treponemal Flocculation Assay
16.4. Market Value Forecast By Test Type, 2020-2034
16.4.1. Treponemal Tests
16.4.2. Non-Treponemal Tests
16.5. Market Value Forecast By Location of Testing, 2020-2034
16.5.1. Point-of-care testing (POCT)
16.5.2. Patient Self-Tests (PST)
16.5.3. Clinical Settings
16.6. Market Value Forecast By End-user, 2020-2034
16.6.1. Hospitals and Clinics
16.6.2. Diagnostics Laboratories
16.6.3. Home Care
16.6.4. Public Health Laboratory
16.6.5. Others
16.7. Market Value Forecast By Country, 2020-2034
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Product
16.8.2. By Technology
16.8.3. By Test Type
16.8.4. By Location of Testing
16.8.5. By End-user
16.8.6. By Country
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Abbott
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Becton, Dickinson, and Company (BD)
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. bioMérieux SA
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Bio-Rad Laboratories, Inc
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Chembio Diagnostics, Inc.
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Danaher Corporation
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. DiaSorin S.p.A.
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Roche Diagnostics (F. Hoffmann-La Roche AG)
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Fujirebio
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. QuidelOrtho Corporation
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. Shenzhen New Industries Biomedical Engineering Co., Ltd.
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
17.3.12. Siemens Healthineers AG
17.3.12.1. Company Overview
17.3.12.2. Financial Overview
17.3.12.3. Product Portfolio
17.3.12.4. Business Strategies
17.3.12.5. Recent Developments
17.3.13. Sekisui Chemical Co Ltd
17.3.13.1. Company Overview
17.3.13.2. Financial Overview
17.3.13.3. Product Portfolio
17.3.13.4. Business Strategies
17.3.13.5. Recent Developments
17.3.14. Thermo Fisher Scientific, Inc.
17.3.14.1. Company Overview
17.3.14.2. Financial Overview
17.3.14.3. Product Portfolio
17.3.14.4. Business Strategies
17.3.14.5. Recent Developments
17.3.15. Trinity Biotech
17.3.15.1. Company Overview
17.3.15.2. Financial Overview
17.3.15.3. Product Portfolio
17.3.15.4. Business Strategies
17.3.15.5. Recent Developments